Before discovering and clarifying the endocrine pathophysiological role of the gastrointestinal system and the effect of incretins on the development of T2D, a class of drugs targeting the small intestinal α-glucosidase enzyme was introduced into clinical practice and, therefore, to decreased glucose absorption. This evidence concerns the gene GCG and type 2 diabetes mellitus.